The list of international projects SAS
Biomedical Research Center SAS
Alliance for Life Sciences: From Strategies to Actions in Central and Eastern Europe
Aliancia pre živé vedy: od stratégií k činom v strednej a východnej Európe
| Duration: |
1.5.2021 - 30.4.2024 |
| Program: |
Horizon 2020 |
| Project leader: |
prof. RNDr. Pastoreková Silvia DrSc. |
| Annotation: | Research and innovation (R&I) plays a pivotal role in addressing Europe’s societal challenges including ensuring health and wellbeing of the citizens. Differences still persist in R&I performance between countries despite significant investments. In the health sector, the R&I gap can profoundly affect the quality of health and life of European citizens. Continuing the success of Alliance4Life, the EU-funded A4L_ACTIONS project aims to tackle the health R&I gap by improving the culture, governance, recognition and innovation potential of the health research-performing institutions in the lower-performing Central and Eastern European countries. This will help increase their attractiveness and pave the way for collaborations with advanced European countries. |
DE-PASS Determinants of Physical Activities in Settings
DE-PASS Determinanty pohybovej aktivity v modernej spoločnosti
European Network for Skin Engineering and Modeling
Európska sieť pre kožné inžinierstvo a modelovanie
European partnership fostering a European Research Area (ERA) for health research
Európske partnerstvo prehlbujúce spoluprácu v rámci Európskeho výskumného priestoru (ERA) pre zdravotnícky výskumu
| Duration: |
1.11.2022 - 30.10.2029 |
| Program: |
Horizon Europe |
| Project leader: |
doc. MUDr. Imrich Richard DrSc. |
| Annotation: | Excellent EU programs push health R&I but are not sufficient. Synergy with strategic initiatives in MS and a new model for impactful collaborations are needed to address the challenges for health. ERA4Health brings the opportunity to increase EU transnational collaborative research funding by creating a funding body for joint programming in priority areas addressing EU Public Health Needs, with total duration of 7 years. ERA4Health focuses on tackling diseases and reducing disease burden and the following challenges: 1) the increasing demand for a better quality of life and a better care of patients, 2) the need to transform public health care systems in more effective, efficient, equitable, accessible, and resilient ones and 3) the need to strengthen disease prevention and health promotion. In this view, ERA4Health objectives are: .SO1- Support relevant medical research including clinical fields and intervention areas (prevention, diagnosis, treatment) .SO2- Improve the utilisation of existing health technologies in clinical practice .SO3- Build capacity, in particular in conducting Investigator Initiated Clinical Studies at EU scale .SO4- Implement and advance the practice of RRI across the breadth of the programme ERA4Heatlth will be implemented in 2 phases: . Phase 1 (2 years) will implement joint calls focused on nutrition and lifestyle-related diseases, cardiovascular diseases and nanomedicine (4 in two years). In parallel, it will establish a supporting framework to overcome the challenges in launching international IICSs joint calls. . Phase 2, if the EC approves it: additional multinational calls for IICSs and joint calls for other priority areas will be launched in accordance with the decision of the Health Programme Committee taken at the end of previous Phase 34 partners (20 from EU, 3 Third Countries associated to HE and 2 non-associated, non EU), will commit 90,510,000€, during the 3 first years, as financial support to third parties. |
European Virus Archive GLOBAL
Európsky vírusový archív GLOBAL
Identification of biological markers for prevention and translational medicine in pancreatic cancer
Identifikácia biologických markerov pre prevenciu a translačnú medicínu pri rakovine pankreasu
| Duration: |
11.10.2022 - 10.10.2026 |
| Program: |
COST |
| Project leader: |
Mgr. Smolková Božena PhD. |
| Annotation: | Pancreatic cancer (PC) has a high mortality rate and is projected to become a massive public health problem in Europe. This Action will boost research on prevention of PC, particularly in the discovery of genetic risk factors, risk stratification, identification of biomarkers for early detection and patient monitoring, elucidation of biological mechanisms and functional pharmacogenomics for personalized medicine. These aims will be attained by expanding an existing interdisciplinary network.
The Action will be organized in the following working groups:
• Disease risk profiling. This WG will use germline genetic variants, epigenetics, transcriptomics and environmental factors to model disease risk and apply risk stratification scores to better select individuals eligible to be screened for PC or its precursors.
• Non-invasive biomarkers. This WG will apply state-of-the-art liquid biopsies for the detection and characterization of circulating tumor cells and DNA, tumor-derived exosomes, tumor-educated platelets, epigenetic markers, and will test their diagnostic value for PC precursors and early-stage PC.
• Tumor profiling. Genomic, epigenomic and transcriptional profiling of PC and its precursors in a multiregional analysis fashion will be used to identify novel biomarkers with prognosis and predictive value for PC patient stratification.
• Functional genomics and therapy. This WG will functionally validate candidate genetic variants from germline or tumor studies by using cutting-edge approaches such as CRISPR-Cas9 gene editing. It will also generate novel approaches such as organoids / zebrafish avatars to implement (chemo)therapeutic strategies based on the patient in an effort to implement personalized medicine for PC. |
Integrated Services for Infectious Disease Outbreak Research
Integrované služby pre výskum prepuknutia infekčných chorôb
Translational control in Cancer European Network
Kontrola translácie v Cancer European Network
A Coordination and Support Action to prepare UNCAN.eu platform
Koordinačná a podporná akcia na prípravu UNCAN.eu platformy
| Duration: |
1.9.2022 - 30.11.2023 |
| Program: |
Horizon Europe |
| Project leader: |
Mgr. Chovanec Miroslav PhD. |
| Annotation: | The aim of the one-year Coordination and Support Action (CSA), called "4.UNCAN.eu", is to design a platform for the UNCAN.eu virtual institute. This platform will represent a research agenda with a limited number of general challenges that need to be urgently addressed at the transnational level by the European research groups. These challenges will be addressed mainly by the large-scale research programs identified through an open, competitive selection process. In case of an identified need, UNCAN.eu will also initiate targeted, smaller-scale calls that will address very specific problems. Challenges and programs will be selected in close collaboration with cancer patient organizations in order to integrate the expectations of the European citizens and cancer patients and their families into the proposed program. The aim of the CSA "4.UNCAN.eu" project is to identify the most challenging gaps in current cancer management and determine how they could be jointly addressed with the European added value. The CSA initiative was founded by a "core consortium" comprising six countries (France, Germany, Hungary, Italy, the Netherlands and Spain), which cooperated with the largest European Cancer Patient Coalition, as well as the Organization of Parents of Children with Cancer and cured children (Childhood Cancer International-Europe). Several "associate partners", including BMC SAS, subsequently expressed interest in joining the core consortium initiative. The researchers from the associated member states will be actively involved in the creation of the platform for the UNCAN.eu virtual institute. |
Genome Editing to Treat Humans Diseases
Liečba chorôb modifikáciou genómu
Metabolic therapy of heart failure: which role for B vitamins
Metabolická terapia srdcového zlyhania: úloha vitamínov B
| Duration: |
1.4.2020 - 31.3.2024 |
| Program: |
ERANET |
| Project leader: |
RNDr. Zahradníková, ml. Alexandra PhD. |
| Annotation: | Heart failure (HF) is a major cause of death worldwide. It is clear that profound modulations of energy
metabolism are involved in the development of HF. This includes a drop in the cardiac levels of energy carrier
compounds, ATP, Phosphocreatine, and nicotinamide adenine dinucleotide (NAD+), a major coenzyme in glycolysis
and mitochondrial ATP generation. In this respect we previously showed, in a mouse model of cardiac pressure
overload, the protective effect of diet supplementation with two vitamins (B12/B9) stimulating the mitochondrial
biogenesis pathways, or with nicotinamide riboside (NR), a recently characterized vitamin B3 which is a NAD+
precursor. Inasmuch as these treatments were given before the appearance of the first symptoms of HF in these
studies, we propose here to test the efficiency of a treatment with a cocktail of these 3 B vitamins in symptomatic
HF in mice to propose an eventual curative use of these vitamins. Our primary aim will be to assess the impact of
treatment on survival, exercise capacities, cardiac function, mitochondrial respiration and dynamics, calcium
metabolism and metabolic fluxes. In a translational perspective toward clinics, we will also assess the impact of this
vitamins B cocktail in the context of standard of care of HF (β-blocker, ACE inhibitor). Finally, it is critically important
to consider the sex differences in treatment of HF. Therefore the second aim of the presented project is to compare
the effect of the treatment in males and females that differ as regards alteration in mitochondrial and calcium
metabolism in HF. |
Modelling immunotherapy response and toxicity in cancer
Modelovanie toxicity a odpovede na imunoterapiu pri liečbe rakoviny
| Duration: |
2.11.2022 - 1.11.2026 |
| Program: |
COST |
| Project leader: |
Mgr. Smolková Božena PhD. |
| Annotation: | The IMMUNO-model COST Action aims to foster research and innovation in the field of preclinical immuno-oncology models with the ultimate goal of advancing in the treatment of cancer patients by improving their outcomes and quality of life. The unprecedented change that immunotherapy has represented in the treatment of cancer is best illustrated by the spectacular results obtained in previously incurable malignancies, such as metastatic melanoma. However, the widespread use of these therapies has been hindered by their limited effectiveness and associated toxicities. A better understanding on the complex interactions between tumor cells and the immune system is strictly required to address these problems, and to develop more effective and safer immunotherapies. However, one of the most important obstacles in immuno-oncology research is the scarcity of preclinical models that faithfully recapitulate human immunity and contribute to identify novel therapeutic targets, characterize biomarkers of therapeutic response and toxicity, and generate reliable data on drug synergies. IMMUNO-model will bring together European researchers from diverse sectors (academia, clinical, industry) with the common goal of establishing a Network that endorses immuno-oncology research by specifically promoting the sharing, standardization and application of immunotherapy preclinical models. |
Myokines and metabolically active molecules in the pathogenesis of idiopathic inflammatory myopathies
Myokíny a metabolicky aktívne molekuly v patogenéze idiopatických zápalových myopatií
UNveiling the MEchanism(s) underlying the switch to mania during antidepressant treatment: The role of glutamate
Odkrytie mechanizmov zodpovedných prešmyk z depresie do mánie počas antidepresívnej liečby: úloha glutamátu
Resistance under treatment in breast cancer
Rezistencia po liečbe u karcinómu prsníka
| Duration: |
1.8.2020 - 31.5.2024 |
| Program: |
ERANET |
| Project leader: |
Mgr. Cihová Marína PhD. |
| Annotation: | The concept behind this project is that by computational algorithms and mathematical modelling integrating data from clinical trials,
ex vivo experimental models, and tumor molecular data at multiple levels will lead to the identification of drivers of resistance.
These will be incorporated into patient-specific therapeutic regimens in a systems medicine approach. A leading edge of RESCUER is
combining state-of-art mathematical modeling to data obtained from clinical trials and cutting-edge cell models to discover patientspecific
therapeutic regimens. The efficacy in overcoming resistance will be evaluated by treating patient-derived xenograft (PDX)
models derived from treatment resistant breast cancer (BC) patients prior to forthcoming clinical trials aimed to enroll patients with
resistant tumors will be designed. The investigation and discovery of effective treatments for subclasses of BC can be performed only upon
a deep understanding of intra-patient and inter-tumor heterogeneity and of the mechanisms of treatment resistance |
TBFVnet: surveillance and research on tick-borne flaviviruses
TBFVnet: sledovanie a výskum flavivírusov prenášaných kliešťami
TEmperature-responsive Nanogels for TArgeted delivery of miCroRNAs in wound heaLing and tissue rEgeneration applicationS
Tepelne senzitívne nanogély pre cielený transport miRNA na liečbu rán a regeneráciu tkanív
| Duration: |
1.2.2020 - 31.1.2024 |
| Program: |
ERANET |
| Project leader: |
RNDr. Šramková Monika PhD. |
| Annotation: | The development of new therapeutically active wound protection agents, which not only protect the injured skin from external influences but also support the healing process itself, has significant potential for clinical applications. The aim of the TENTACLES project is to develop an innovative multifunctional nanogel that integrates protective (nanohydrogel) and healing functions (iron oxide nanoparticles and targeted miRNAs) within one nanocomposite intelligent structure. The nanohydrogel fulfills a protective function, while the iron oxide nanoparticles, due to mild hyperthermia, promote the induction of HSP (heat shock protein) and miRNAs, which play a key role in the healing process of wound healing. The innovative nanocomposite nanohydrogel provides a revolutionary wound healing strategy, especially for diabetic patients.
|
Role of the CA IX ectodomain in tumor growth and metastasis
Úloha ektodomény CA IX v nádorovom raste a metastázovaní
| Duration: |
11.11.2014 - 31.12.2023 |
| Program: |
Other |
| Project leader: |
prof. RNDr. Pastoreková Silvia DrSc. |
| Annotation: | This project is aimed at understanding the role of the CA IX ECD in tumor growth and metastasis in vivo using mouse models. We intend to evaluate growth of tumor xenografts (following subcutaneous implantation of tumor cells) and colonization of lungs (following injection of tumor cells into the tail vein) in absence and presence of the recombinant CA IX ECD. In addition, we plan to evaluate potential therapeutic targeting of CA IX ECD through analysis of the anticancer effect of antibodies binding to different regions of the ectodomain, including M75 and VII/20. Particularly M75 is of great interest, because the N-terminal PG region, to which M75 binds, was recently found to be involved in cell adhesion and spreading, the processes contributing to metastatic dissemination. On the other hand, MAb VII/20 binds to the central CA catalytic domain and was previously shown to reduce the growth of primary tumors, but its effect on metastasis has not been examined so far.
Thus, we expect that the project will allow us to dissect the role of ECD in metastasis and propose antibody-based therapeutic strategies to reduce metastatic growth.
|
VACCELERATE - European Corona Vaccine Trial Accelerator Platform
VACCELERATE - Európska platforma na akceleráciu klinického skúšania vakcín proti novému koronavírusu
| Duration: |
28.1.2021 - 27.1.2024 |
| Program: |
Horizon 2020 |
| Project leader: |
prof. RNDr. Pastoreková Silvia DrSc. |
| Annotation: | The COVID-19 pandemic has underscored the need for concerted efforts towards vaccine development in Europe. The EU-funded VACCELERATE project creates a platform connecting all European vaccine development stakeholders. VACCELERATE maps clinical trial and laboratory sites across Europe and identifies the best locations for conducting Phase 2 and 3 vaccine trials. A Volunteer Registry provides access to trial participants. The network coordinates laboratory support and provides standardised assays and trial protocols. VACCELERATE identifies and shares emerging public health questions, provides answers through its own clinical trials, and lends expertise and tangible support to vaccine developers from industry and academia. With these efforts, VACCELERATE partners are creating a network ready to face emerging pandemics and enhance vaccine development capacity in Europe. |
The total number of projects: 19
